chemieunternehmen.com

The 12th edition is dedicated to our exciting new developments in pre-clinical cellular models with a particular focus on three-dimensional (3D) cell culture platforms, including microtissues, organoids and organ-on-a-chip systems. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-12—evotecs-3d-cell-model-platform-6151

Evotec SE today presents at its virtual Capital Markets Day how artificial intelligence (“AI”) and machine learning (“ML”) enabled precision technologies in discovery and development processes are driving up Probability of Success (“PoS”), i.e. an increasing rate of approvals in the long-run. To leverage the power of molecular data, Evotec is launching E.MPD, the Company’s molecular patient database. E.MPD is one of the largest and highest quality molecular databases globally. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-presents-strategic-roadmap-towards-precision-medicine-and-confirms-goals-of-action-plan-2025-at-capital-markets-day-6149

Evotec SE announced today that the Company has entered into a collaboration with the University of Bristol (“UoB”) to expand the Company’s molecular patient database in the field of kidney diseases with a focus on nephrotic syndrome. The nephrotic syndrome is a group of symptoms like proteinuria and oedema that indicate kidneys are not working properly. Diagnosis remains challenging and current treatment regimens are mostly symptomatic. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-molecular-patient-database-with-unique-nephrotic-syndrome-cohort-from-the-university-of-bristol-6147